Zobrazeno 1 - 10
of 1 519
pro vyhledávání: '"her3"'
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 143-148 (2024)
Brinda Gupta, Laura Gosa Barrett, Stephen V Liu Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USACorrespondence: Stephen V Liu, Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washin
Externí odkaz:
https://doaj.org/article/f3272f10ef1f4ecc9a3143e1ad38b2bf
Autor:
Meiying Zhu, Minghui Yu, Yuan Meng, Jie Yang, Xuerui Wang, Longhui LI, Yangyueying Liang, Fanming Kong
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Metastatic breast cancer (mBC) poses a significant threat to women's health and is a major cause of malignant neoplasms in women. Human epidermal growth factor receptor (HER)3, an integral member of the ErbB/HER receptor tyrosine kinase fami
Externí odkaz:
https://doaj.org/article/4888fc17c3c3420fade8715e6922879d
Autor:
Nicoleta Sinevici, Christine E. Edmonds, Brian N. Dontchos, Gary Wang, Constance D. Lehman, Steven Isakoff, Umar Mahmood
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-16 (2024)
Abstract Purpose HER3, a member of the EGFR receptor family, plays a central role in driving oncogenic cell proliferation in breast cancer. Novel HER3 therapeutics are showing promising results while recently developed HER3 PET imaging modalities aid
Externí odkaz:
https://doaj.org/article/3cedc56817ad4450ac02fb6c9a7e53d0
Autor:
Ann-Katharina Becker, Behrus Puladi, Kunpeng Xie, Angela Cassataro, Rebekka Götzl, Frank Hölzle, Justus P. Beier, Ruth Knüchel-Clarke, Till Braunschweig
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Liposarcomas are among the most common mesenchymal malignancies. However, the therapeutic options are still very limited and so far, targeted therapies had not yet been established. Immunotherapy, which has been a breakthrough in
Externí odkaz:
https://doaj.org/article/c2107f0aff2548f4abc4d7f7832de02c
Autor:
Ernesto Bermúdez-Abreut, Gretchen Bergado Báez, Melissa Martínez Pestano, Giuseppe Attanasio, Carlos Yordan Gonzales Castillo, Diana Rosa Hernández Fernández, Rydell Alvarez-Arzola, Andrea Alimonti, Belinda Sánchez-Ramírez
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Despite the cumulative evidence supporting HER3 as a target for antitumor therapies, no agents targeting HER3 have been approved for cancer treatment. Most of the agents evaluated in preclinical and clinical trials have been specific monoclonal antib
Externí odkaz:
https://doaj.org/article/4b33dc6141334ea3b681860235503286
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background HER3 (ErbB3), a member of the human epidermal growth factor receptor family, is frequently overexpressed in various cancers. Multiple HER3-targeting antibodies and antibody–drug conjugates (ADCs) were developed for the solid tum
Externí odkaz:
https://doaj.org/article/a4b5c497a3f642b5a29caee4adf52aee
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-16 (2023)
Abstract Background Triple negative breast cancer (TNBC) represents a significant clinical challenge. Chemotherapy remains the mainstay for a large part of TNBC patients, whereas drug resistance and tumor recurrence frequently occur. It is in urgent
Externí odkaz:
https://doaj.org/article/92a5e08a19c24a24943b9ec17a0c687e
Publikováno v:
Pharmaceutics, Vol 16, Iss 7, p 890 (2024)
Current therapies targeting the human epidermal growth factor receptor (HER) family, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs), are limited by drug resistance and systemic toxicities. Antibody–drug conjugates (ADC
Externí odkaz:
https://doaj.org/article/663e8b0bd3404895b93282ecf8dcc9dc
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/edfafdc3548e41ca9fcd55a183a80298
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
Receptor tyrosine kinases (RTKs) play a crucial role in cellular signaling and oncogenic progression. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have become the standard treatment for advanced non-small cell lung cancer (
Externí odkaz:
https://doaj.org/article/1f5281f73d9540c9aae7ef6f8d8ccdc0